Cynvenio Biosystems Inc, Westlake Village, Calif, has launched the Concordia cell-free DNA (cfDNA) sample preparation upgrade for its multitemplate LiquidBiopsy platform. When coupled with Ion Torrent next-generation sequencing (NGS) systems from Thermo Fisher Scientific, Waltham, Mass, Cynvenio’s workflow provides comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw.
The Concordia option, which consists of a hardware module and a software upgrade installed remotely, is now available to early access customers through the company’s partnership with Thermo Fisher Scientific. The cfDNA upgrade enables users to purify DNA from whole blood using Thermo Fisher’s Applied Biosystems MagMax cell-free DNA isolation kit, an integrated system designed to simplify, standardize, and accelerate preparation of samples derived from various sources for downstream molecular analysis. Full commercial release of the upgrade kit is scheduled for the second quarter of this year.
Paul Dempsey, Cynvenio.
“Our LiquidBiopsy platform is the first and only automated enrichment system to produce multiple templates from a single blood sample for downstream molecular characterization by NGS,” says Paul Dempsey, chief science officer at Cynvenio. “Our approach enables clinical researchers to simultaneously sequence circulating tumor DNA as well as DNA from circulating tumor cells (CTCs) for the most comprehensive readout of tumor variants. Providing automated multitemplate sample preparation on our platform simplifies lab workflows and ensures quality nucleic acid material for downstream analysis. Moreover, we expect this technology will help better inform patient care in the future.”
“We strive to provide our customers with the best automated solutions to enhance their clinical research and simplify lab workflows,” says Jason Johnson, senior director of oncology product management in the clinical sequencing business at Thermo Fisher Scientific. “We are very pleased to offer Cynvenio’s Concordia upgrade to our LiquidBiopsy platform customers, enabling greater workflow efficiencies with their research by allowing them to achieve multitemplate sample preparation of cfDNA and CTCs on a single instrument.”
For more information, visit Cynvenio.
